Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 359
Filter
1.
Allergy ; 73(5): 1003-1012, 2018 05.
Article in English | MEDLINE | ID: mdl-29083477

ABSTRACT

BACKGROUND: Administration of the therapeutic anti-IgE antibody omalizumab to patients induces strong increases in IgE antibody levels. OBJECTIVE: To investigate the effect of intranasal administration of major birch pollen allergen Bet v 1, omalizumab or placebo on the levels of total and allergen-specific IgE in patients with birch pollen allergy. METHODS: Based on the fact that intranasal allergen application induces rises of systemic allergen-specific IgE, we performed a double-blind placebo-controlled pilot trial in which birch pollen allergic subjects were challenged intranasally with omalizumab, placebo or birch pollen allergen Bet v 1. Total and allergen-specific IgE, IgG and basophil sensitivity were measured before and 8 weeks after challenge. For control purposes, total, allergen-specific IgE levels and omalizumab-IgE complexes as well as specific IgG levels were studied in subjects treated subcutaneously with either omalizumab or placebo. Effects of omalizumab on IgE production by IL-4/anti-CD40-treated PBMCs from allergic patients were studied in vitro. RESULTS: Intranasal challenge with Bet v 1 induced increases in Bet v 1-specific IgE levels by a median of 59.2%, and this change differed significantly from the other treatment groups (P = .016). No relevant change in allergen-specific and total IgE levels was observed in subjects challenged with omalizumab. Addition of omalizumab did not enhance IL-4/anti-CD40-induced IgE production in vitro. Significant rises in total IgE (mean IgE before: 131.83 kU/L to mean IgE after: 505.23 kU/L) and the presence of IgE-omalizumab complexes were observed after subcutaneous administration of omalizumab. CONCLUSION: Intranasal administration of allergen induced rises of allergen-specific IgE levels, whereas intranasal administration of omalizumab did not enhance systemic total or allergen-specific IgE levels.


Subject(s)
Anti-Allergic Agents/administration & dosage , Antigens, Plant/immunology , Immunoglobulin E/immunology , Omalizumab/administration & dosage , Rhinitis, Allergic, Seasonal/immunology , Administration, Intranasal , Adult , Allergens/administration & dosage , Allergens/immunology , Antigens, Plant/administration & dosage , Double-Blind Method , Female , Humans , Immunoglobulin E/analysis , Male , Pilot Projects , Young Adult
2.
Physiol Int ; 104(3): 258-269, 2017 Sep 01.
Article in English | MEDLINE | ID: mdl-28956639

ABSTRACT

Aims The aim of this study was to examine the effects of gender on the relationship between Functional Movement Screen (FMS) and treadmill-based gait parameters. Methods Twenty elite junior athletes (10 women and 10 men) performed the FMS tests and gait analysis at a fixed speed. Between-gender differences were calculated for the relationship between FMS test scores and gait parameters, such as foot rotation, step length, and length of gait line. Results Gender did not affect the relationship between FMS and treadmill-based gait parameters. The nature of correlations between FMS test scores and gait parameters was different in women and men. Furthermore, different FMS test scores predicted different gait parameters in female and male athletes. FMS asymmetry and movement asymmetries measured by treadmill-based gait parameters did not correlate in either gender. Conclusion There were no interactions between FMS, gait parameters, and gender; however, correlation analyses support the idea that strength and conditioning coaches need to pay attention not only to how to score but also how to correctly use FMS.


Subject(s)
Athletic Performance/physiology , Exercise Test/methods , Gait/physiology , Physical Examination/methods , Sex Factors , Sports/physiology , Adolescent , Female , Humans , Male , Reproducibility of Results , Sensitivity and Specificity , Young Adult
3.
J Sci Med Sport ; 20(6): 528-533, 2017 Jun.
Article in English | MEDLINE | ID: mdl-28089102

ABSTRACT

OBJECTIVES: To compare three different ultrasound-guided injections for chronic tennis elbow. DESIGN: Assessor-blinded, randomized controlled comparative trial. METHODS: 44 patients with clinically diagnosed tennis elbow, confirmed by Doppler ultrasound, received under ultrasound guidance, a single corticosteroid injection (n=14), or two injections (separated by 4 weeks) of either autologous blood (n=14) or polidocanol (n=16). Clinical and ultrasound examination was performed at baseline, 4, 12 and 26 weeks. RESULTS: Complete recovery or much improvement was greater for corticosteroid injection than autologous blood and polidocanol at 4 weeks (p<0.001, number needed to treat 1 (95% CI 1-2)). In contrast, at 26 weeks corticosteroid was significantly worse than polidocanol (p=0.004, number needed to harm 2 (1-6)). Recurrence after corticosteroid injection was significantly higher than autologous blood or polidocanol (p=0.007, number needed to harm 2 (1-4)). Corticosteroid injection produced greater reduction in tendon thickness and vascularity than autologous blood at 4 weeks only. Compared to autologous blood, polidocanol reduced tendon thickness at 4 and 12 weeks and reduced echogenicity and hyperaemia after 12 or 26 weeks respectively. CONCLUSIONS: Injections of corticosteroid cannot be recommended over polidocanol or autologous blood, because despite beneficial short-term effect there were inferior long-term effects. Whether polidocanol or autologous blood injections are effective is unknown, especially as their global effect profiles are not unlike previously reported for wait-and-see.


Subject(s)
Adrenal Cortex Hormones/therapeutic use , Anti-Inflammatory Agents/therapeutic use , Blood Transfusion, Autologous , Polyethylene Glycols/therapeutic use , Sclerosing Solutions/therapeutic use , Tennis Elbow/therapy , Adult , Female , Follow-Up Studies , Humans , Injections , Male , Middle Aged , Polidocanol , Single-Blind Method , Tennis Elbow/diagnostic imaging , Treatment Outcome , Ultrasonography, Doppler, Color , Ultrasonography, Interventional
4.
Scand J Immunol ; 84(3): 174-81, 2016 Sep.
Article in English | MEDLINE | ID: mdl-27312152

ABSTRACT

In patients with typical angina pectoris, inducible myocardial ischaemia and macroscopically normal coronaries (cardiac syndrome X (CSX)), a significantly elevated plasma level of terminal complement complex (TCC), the common end product of complement activation, has been observed without accompanying activation of the classical or the alternative pathways. Therefore, our aim was to clarify the role of the ficolin-lectin pathway in CSX. Eighteen patients with CSX, 37 stable angina patients with significant coronary stenosis (CHD) and 54 healthy volunteers (HC) were enrolled. Serum levels of ficolin-2 and ficolin-3, ficolin-3/MASP-2 complex and ficolin-3-mediated TCC deposition (FCN3-TCC) were determined. Plasma level of TCC was significantly higher in the CSX than in the HC or CHD group (5.45 versus 1.30 versus 2.04 AU/ml, P < 0.001). Serum levels of ficolin-2 and ficolin-3 were significantly lower in the CSX compared to the HC or CHD group (3.60 versus 5.80 or 5.20 µg/ml, P < 0.05; 17.80 versus 24.10 or 26.80 µg/ml, P < 0.05). The ficolin-3/MASP-2 complex was significantly lower in the CSX group compared to the HC group (92.90 versus 144.90 AU/ml, P = 0.006). FCN3-TCC deposition was significantly lower in the CSX group compared to the HC and CHD groups (67.8% versus 143.3% or 159.7%, P < 0.05). In the CSX group, a significant correlation was found between TCC and FCN3-TCC level (r = 0.507, P = 0.032) and between ficolin-3/MASP-2 complex level and FCN3-TCC deposition (r = 0.651, P = 0.003). In conclusion, in patients with typical angina and myocardial ischaemia despite macroscopically normal coronary arteries, low levels of several lectin pathway parameters were observed, indicating complement activation and consumption. Complement activation through the ficolin-lectin pathway might play a role in the complex pathomechanism of CSX.


Subject(s)
Complement Membrane Attack Complex/genetics , Complement Pathway, Mannose-Binding Lectin/genetics , Glycoproteins/immunology , Lectins/immunology , Mannose-Binding Protein-Associated Serine Proteases/immunology , Microvascular Angina/immunology , Adult , Case-Control Studies , Enzyme-Linked Immunosorbent Assay , Female , Gene Expression Regulation , Glycoproteins/blood , Glycoproteins/genetics , Humans , Lectins/blood , Lectins/genetics , Male , Mannose-Binding Protein-Associated Serine Proteases/genetics , Microvascular Angina/blood , Microvascular Angina/genetics , Microvascular Angina/pathology , Middle Aged , Signal Transduction , Ficolins
5.
Neth Heart J ; 24(7-8): 491, 2016 Jul.
Article in English | MEDLINE | ID: mdl-27277788
6.
Neth Heart J ; 24(7-8): 488, 2016 Jul.
Article in English | MEDLINE | ID: mdl-27277789
7.
Physiol Int ; 103(1): 86-93, 2016 Mar.
Article in English | MEDLINE | ID: mdl-27030630

ABSTRACT

The goal of the study was to find a proper technique to fix tendon grafts into an INSTRON loading machine. From 8 human cadavers, 40 grafts were collected. We removed the bone-patella tendon-bone grafts, the semitendinosus and gracilis tendons, the quadriceps tendon-bone grafts, the Achilles tendons, and the peroneus longus tendons from each lower extremity. We tested the tendon grafts with five different types of fixation devices: surgical thread (Premicron 3), general mounting clamp, wire mesh, cement fixation, and a modified clamp for an INSTRON loading machine. The mean failure load in case of surgical thread fixation was (381N ± 26N). The results with the general clamp were (527N ± 45N). The wire meshes were more promising (750N ± 21N), but did not reach the outcomes we desired. Easy slippages of the ends of the tendons from the cement encasements were observed (253N ± 18N). We then began to use Shi's clamp that could produce 977N ± 416N peak force. We combined Shi's clamp with freezing of the graft and the rupture of the tendon itself demonstrated an average force of 2198 N ± 773N. We determined that our modified frozen clamp fixed the specimens against high tensile forces.


Subject(s)
Biomechanical Phenomena/physiology , Materials Testing , Stress, Mechanical , Tendons/physiology , Tissue Fixation/methods , Cadaver , Elastic Modulus , Humans , Materials Testing/instrumentation , Materials Testing/methods , Materials Testing/standards , Muscle Strength/physiology , Muscle, Skeletal/pathology , Muscle, Skeletal/physiology , Resin Cements/chemistry , Tendons/pathology , Tissue Donors , Tissue and Organ Harvesting/methods , Tissue and Organ Harvesting/standards , Weight-Bearing/physiology
8.
Oncogene ; 35(30): 3976-85, 2016 07 28.
Article in English | MEDLINE | ID: mdl-26686091

ABSTRACT

Photosensitizers (PS) are ideally devoid of any activity in the absence of photoactivation, and rely on molecular oxygen for the formation of singlet oxygen ((1)O2) to produce cellular damage. Off-targets and tumor hypoxia therefore represent obstacles for the use of PS for cancer photodynamic therapy. Herein, we describe the characterization of OR141, a benzophenazine compound identified through a phenotypic screening for its capacity to be strictly activated by light and to kill a large variety of tumor cells under both normoxia and hypoxia. This new class of PS unraveled an unsuspected common mechanism of action for PS that involves the combined inhibition of the mammalian target of rapamycin (mTOR) signaling pathway and proteasomal deubiquitinases (DUBs) USP14 and UCH37. Oxidation of mTOR and other endoplasmic reticulum (ER)-associated proteins drives the early formation of high molecular weight (MW) complexes of multimeric proteins, the concomitant blockade of DUBs preventing their degradation and precipitating cell death. Furthermore, we validated the antitumor effects of OR141 in vivo and documented its highly selective accumulation in the ER, further increasing the ER stress resulting from (1)O2 generation upon light activation.


Subject(s)
Deubiquitinating Enzymes/antagonists & inhibitors , Endoplasmic Reticulum/drug effects , Neoplasms/drug therapy , Oxygen/pharmacology , Photochemotherapy , Photosensitizing Agents/pharmacology , Animals , Cell Hypoxia , Cell Line, Tumor , Humans , Mice , Neoplasms/metabolism , Oxidation-Reduction , Proteasome Endopeptidase Complex/metabolism , TOR Serine-Threonine Kinases/physiology
9.
Acta Physiol Hung ; 102(3): 252-62, 2015 Sep.
Article in English | MEDLINE | ID: mdl-26551741

ABSTRACT

BACKGROUND: Catheter ablation is a proven therapy of focal atrial tachycardia. However limited information is available about the additional value of electroanatomical over conventional mapping methods for this specific arrhythmia. METHODS: Consecutive catheter ablation procedures of FAT were analyzed in two cardiology centres. Only conventional mapping was used in 30 of the 60 procedures whereas additionally CARTO mapping was performed in another 30 procedures. Acute, six-month success rate, and procedural data were analyzed. RESULTS: Localization of ectopic foci is congruent with previously published data. There was no statistically significant difference between procedure time and fluoroscopy time using additionally CARTO mapping, compared to conventional mapping only. Acute success rate was higher in procedures guided by CARTO mapping than in procedures based on conventional mapping (27/30 vs. 18/30, p = 0.0081). During the 6-month follow-up period there was a better outcome (p = 0.045) in case of CARTO guided procedures (success: 11 cases, partial success: 12 cases, failure: 4 cases) compared to conventional mapping (success: 4 cases, partial success: 18 cases, failure: 7 cases). CONCLUSIONS: Catheter ablation of focal atrial tachycardias using the CARTO electroanatomical mapping system seems to provide higher acute and 6-month success rate compared to ablation using conventional mapping methods only.


Subject(s)
Catheter Ablation/methods , Electrophysiologic Techniques, Cardiac , Heart Atria/surgery , Tachycardia, Ectopic Atrial/surgery , Action Potentials , Adult , Aged , Aged, 80 and over , Female , Heart Atria/physiopathology , Humans , Hungary , Male , Middle Aged , Predictive Value of Tests , Recurrence , Retrospective Studies , Risk Factors , Tachycardia, Ectopic Atrial/diagnosis , Tachycardia, Ectopic Atrial/physiopathology , Time Factors , Treatment Outcome , Young Adult
10.
J Photochem Photobiol B ; 152(Pt B): 335-46, 2015 Nov.
Article in English | MEDLINE | ID: mdl-26321219

ABSTRACT

Comparative analysis of in vivo chlorophyll fluorescence imaging revealed that photosystem II (PSII) photochemical efficiency (Fv/Fm) of leaves of the Costata 2/133 pea mutant with altered pigment composition and decreased level of oligomerization of the light harvesting chlorophyll a/b-protein complexes (LHCII) of PSII (Dobrikova et al., 2000; Ivanov et al., 2005) did not differ from that of WT. In contrast, photosystem I (PSI) activity of the Costata 2/133 mutant measured by the far-red (FR) light inducible P700 (P700(+)) signal exhibited 39% lower steady state level of P700(+), a 2.2-fold higher intersystem electron pool size (e(-)/P700) and higher rate of P700(+) re-reduction, which indicate an increased capacity for PSI cyclic electron transfer (CET) in the Costata 2/133 mutant than WT. The mutant also exhibited a limited capacity for state transitions. The lower level of oxidizable P700 (P700(+)) is consistent with a lower amount of PSI related chlorophyll protein complexes and lower abundance of the PsaA/PsaB heterodimer, PsaD and Lhca1 polypeptides in Costata 2/133 mutant. Exposure of WT and the Costata 2/133 mutant to high light stress resulted in a comparable photoinhibition of PSII measured in vivo, although the decrease of Fv/Fm was modestly higher in the mutant plants. However, under the same photoinhibitory conditions PSI photochemistry (P700(+)) measured as ΔA820-860 was inhibited to a greater extent (50%) in the Costata 2/133 mutant than in the WT (22%). This was accompanied by a 50% faster re-reduction rate of P700(+) in the dark indicating a higher capacity for CET around PSI in high light treated mutant leaves. The role of chloroplast thylakoid organization on the stability of the PSI complex and its susceptibility to high light stress is discussed.


Subject(s)
Light-Harvesting Protein Complexes/chemistry , Light , Mutation , Photosystem I Protein Complex/antagonists & inhibitors , Pisum sativum/genetics , Pisum sativum/radiation effects , Protein Multimerization/genetics , Chlorophyll/metabolism , Chlorophyll A , Light-Harvesting Protein Complexes/metabolism , Pisum sativum/enzymology , Pisum sativum/metabolism , Photosystem I Protein Complex/chemistry , Photosystem I Protein Complex/metabolism , Protein Structure, Quaternary , Spectrometry, Fluorescence
11.
Neth Heart J ; 22(11): 527, 2014 Nov.
Article in English | MEDLINE | ID: mdl-25319485
12.
Neth Heart J ; 22(11): 530, 2014 Nov.
Article in English | MEDLINE | ID: mdl-25336279
13.
Nat Prod Res ; 28(17): 1322-7, 2014.
Article in English | MEDLINE | ID: mdl-24678783

ABSTRACT

We have studied the ethyl acetate fraction of the methanolic extract of the root barks of Calotropis procera (Asclepiadaceae) from Egypt. Bioassay-directed fractionation and final purification of the extract resulted in the identification of a new cardenolide glycoside named proceraside A (1) together with two known compounds, frugoside (2) and calotropin (3). Their structures were elucidated by extensive NMR studies and mass spectrometric data. The in vitro cytotoxicity of the isolated compounds was evaluated against A549 non-small cell lung cancer, U373 glioblastoma and PC-3 prostate cancer cell lines. They showed potent activity against the tested cancer cell lines with IC50 ranging from 0.005 to 0.3 µg/mL. Cisplatin was used as positive control.


Subject(s)
Calotropis/chemistry , Cardiac Glycosides/isolation & purification , Cardiac Glycosides/pharmacology , Antineoplastic Agents, Phytogenic/chemistry , Cardenolides/chemistry , Cardiac Glycosides/chemistry , Drug Screening Assays, Antitumor , Egypt , Humans , In Vitro Techniques , Male , Plant Bark/chemistry , Prostatic Neoplasms/drug therapy
14.
Neth Heart J ; 22(5): 255-6, 2014 May.
Article in English | MEDLINE | ID: mdl-24700350
15.
Neth Heart J ; 22(5): 253, 2014 May.
Article in English | MEDLINE | ID: mdl-24705930
16.
Chirurgia (Bucur) ; 109(6): 774-82, 2014.
Article in English | MEDLINE | ID: mdl-25560500

ABSTRACT

BACKGROUND: Severe acute pancreatitis (SAP) is still related to high mortality rates. This study evaluated the various surgical strategies for treatment of suspected infected necroziting pancreatitis (INP). METHODS: This retrospective study included 212 patients with SAP and INP, who had surgical treatment during the period between January 2000 - December 2012 at the Ist Surgical Clinic. Surgical approaches included laparostomy with continous postoperative retropancreatic lavage, open abdomen strategy, laparotomy with primary abdominal closure accompanied or not by laparostomy (marsupialization), retroperiostomy with retroperitoneal lavage. RESULTS: The overall mortality rate was 34.0 percent, with 24 percent in laparotomy with continous retropancreatic lavage,11 percent for retroperitoneostomy and retroperitoneal continous lavage, 71 percent for the open abdomen strategy,and 43 percent for laparotomy with closed abdomen(p 0.001). Acute operations, alcoholic origin, Apache II scores of ‰¥10 organ dysfunction on admission were independent factors that predisposed patients to complications.Colonic necrosis with high mortality rates (53 percent), however seemed to be of prognostic relevance. CONCLUSIONS: The conservative approach in severe acutepancreatitis is a promising therapeutic concept. Delaying surgery up to the third week after onset of disease significantly improves the patients€™ survival. Complications are common in severe necrotizing pancreatitis leading to organ failure and need for acute operations. Colonic necros is is an independent prognostic factor for survival.


Subject(s)
Pancreatectomy , Pancreatitis, Acute Necrotizing/surgery , Therapeutic Irrigation , APACHE , Adult , Aged , Female , Humans , Male , Middle Aged , Pancreatectomy/methods , Pancreatitis, Acute Necrotizing/diagnosis , Pancreatitis, Acute Necrotizing/mortality , Prognosis , Retroperitoneal Space/surgery , Retrospective Studies , Risk Assessment , Risk Factors , Survival Analysis , Therapeutic Irrigation/methods , Treatment Outcome
17.
Int J Clin Pract ; 67(6): 516-26, 2013 Jun.
Article in English | MEDLINE | ID: mdl-23557519

ABSTRACT

Atrial fibrillation (AF) is associated with an increased risk of thromboembolism, and is the most prevalent factor for cardioembolic stroke. Vitamin K antagonists (VKAs) have been the standard of care for stroke prevention in patients with AF since the early 1990s. They are very effective for the prevention of cardioembolic stroke, but are limited by factors such as drug-drug interactions, food interactions, slow onset and offset of action, haemorrhage and need for routine anticoagulation monitoring to maintain a therapeutic international normalised ratio (INR). Multiple new oral anticoagulants have been developed as potential replacements for VKAs for stroke prevention in AF. Most are small synthetic molecules that target thrombin (e.g. dabigatran etexilate) or factor Xa (e.g. rivaroxaban, apixaban, edoxaban, betrixaban, YM150). These drugs have predictable pharmacokinetics that allow fixed dosing without routine laboratory monitoring. Dabigatran etexilate, the first of these new oral anticoagulants to be approved by the United States Food and Drug Administration and the European Medicines Agency for stroke prevention in patients with non-valvular AF, represents an effective and safe alternative to VKAs. Under the auspices of the Regional Anticoagulation Working Group, a multidisciplinary group of experts in thrombosis and haemostasis from Central and Eastern Europe, an expert panel with expertise in AF convened to discuss practical, clinically important issues related to the long-term use of dabigatran for stroke prevention in non-valvular AF. The practical information reviewed in this article will help clinicians make appropriate use of this new therapeutic option in daily clinical practice.


Subject(s)
Anticoagulants/administration & dosage , Atrial Fibrillation/drug therapy , Benzimidazoles/administration & dosage , Pyridines/administration & dosage , Stroke/prevention & control , Administration, Oral , Anticoagulants/adverse effects , Benzimidazoles/adverse effects , Dabigatran , Drug Interactions , Dyspepsia/chemically induced , Dyspepsia/prevention & control , Electric Countershock/adverse effects , Hemorrhage/chemically induced , Hemorrhage/prevention & control , Humans , Myocardial Infarction/chemically induced , Patient Selection , Pyridines/adverse effects , Randomized Controlled Trials as Topic , Stents , Treatment Outcome
18.
Cell Death Dis ; 4: e561, 2013 Mar 28.
Article in English | MEDLINE | ID: mdl-23538442

ABSTRACT

Glioblastoma multiforme (GBM) is the most lethal and common malignant human brain tumor. The intrinsic resistance of highly invasive GBM cells to radiation- and chemotherapy-induced apoptosis accounts for the generally dismal treatment outcomes. This study investigated ophiobolin A (OP-A), a fungal metabolite from Bipolaris species, for its promising anticancer activity against human GBM cells exhibiting varying degrees of resistance to proapoptotic stimuli. We found that OP-A induced marked changes in the dynamic organization of the F-actin cytoskeleton, and inhibited the proliferation and migration of GBM cells, likely by inhibiting big conductance Ca(2+)-activated K(+) channel (BKCa) channel activity. Moreover, our results indicated that OP-A induced paraptosis-like cell death in GBM cells, which correlated with the vacuolization, possibly brought about by the swelling and fusion of mitochondria and/or the endoplasmic reticulum (ER). In addition, the OP-A-induced cell death did not involve the activation of caspases. We also showed that the expression of BKCa channels colocalized with these two organelles (mitochondria and ER) was affected in this programmed cell death pathway. Thus, this study reveals a novel mechanism of action associated with the anticancer effects of OP-A, which involves the induction of paraptosis through the disruption of internal potassium ion homeostasis. Our findings offer a promising therapeutic strategy to overcome the intrinsic resistance of GBM cells to proapoptotic stimuli.


Subject(s)
Antineoplastic Agents/pharmacology , Brain Neoplasms/metabolism , Endoplasmic Reticulum/drug effects , Glioblastoma/metabolism , Large-Conductance Calcium-Activated Potassium Channel alpha Subunits/antagonists & inhibitors , Mitochondria/drug effects , Sesterterpenes/pharmacology , Actins/antagonists & inhibitors , Actins/metabolism , Brain Neoplasms/drug therapy , Brain Neoplasms/pathology , Cell Death/drug effects , Cell Death/physiology , Cell Line, Tumor , Cell Movement/drug effects , Cell Proliferation/drug effects , Drug Resistance, Neoplasm/drug effects , Endoplasmic Reticulum/metabolism , Endoplasmic Reticulum/pathology , Glioblastoma/drug therapy , Glioblastoma/pathology , Homeostasis/drug effects , Homeostasis/physiology , Humans , Large-Conductance Calcium-Activated Potassium Channel alpha Subunits/metabolism , Membrane Potentials/drug effects , Mitochondria/metabolism , Mitochondria/pathology , Patch-Clamp Techniques , Potassium/metabolism
19.
Mini Rev Med Chem ; 12(13): 1315-29, 2012 Nov.
Article in English | MEDLINE | ID: mdl-23016545

ABSTRACT

Various types of cancers (including gliomas, melanomas, and esophageal, pancreas and non-small-cell lung cancers) display intrinsic resistance to pro-apoptotic stimuli, such as conventional chemotherapy and radiotherapy, and/or the activation of a multidrug resistance phenotype, which are major barriers to effective treatment and lead to poor patient prognosis. The DYRK1A kinase is directly implicated in the resistance of cancer cells to pro-apoptotic stimuli and drives several pathways that enhance proliferation, migration, and the reduction of cell death, leading to very aggressive biological behavior in cancer cell populations. The DYRK1A kinase is also implicated in neurological diseases and in neoangiogenic processes. Thus, the DYRK1A kinase is of great interest for both cancer and neuroscience research. During the last decade, numerous compounds that inhibit DYRK1A have been synthesized. The present review discusses the available molecules known to interfere with DYRK1A activity and the implications of DYRK1A in cancer and other diseases and serves as a rational analysis for researchers who aim to improve the anti-DYRK1A activity of currently available compounds.


Subject(s)
Neoplasms/enzymology , Protein Kinase Inhibitors/pharmacology , Protein Serine-Threonine Kinases/antagonists & inhibitors , Protein-Tyrosine Kinases/antagonists & inhibitors , Animals , Humans , Protein Kinase Inhibitors/chemistry , Protein Kinase Inhibitors/metabolism , Protein Serine-Threonine Kinases/chemistry , Protein Serine-Threonine Kinases/metabolism , Protein-Tyrosine Kinases/chemistry , Protein-Tyrosine Kinases/metabolism , Structure-Activity Relationship , Dyrk Kinases
20.
Nat Prod Rep ; 29(4): 487-501, 2012 Apr.
Article in English | MEDLINE | ID: mdl-22337153

ABSTRACT

Phenazines are a large group of natural and synthesised nitrogen-containing heterocycles, including more than 100 different compounds of natural origin and over 6000 synthetic compounds. Many of these compounds have been investigated as potential anti-cancer agents. Despite a large number of research publications, no recent attempt to summarise and critically evaluate the experimental findings relating to the anti-cancer activity of this class of compounds has been made. The present review fills this gap in the literature and discusses both natural and synthetic phenazines with a critical focus on in vitro, in vivo and available clinical anti-cancer activities of these compounds.


Subject(s)
Antineoplastic Agents , Phenazines , Antineoplastic Agents/chemical synthesis , Antineoplastic Agents/chemistry , Antineoplastic Agents/isolation & purification , Antineoplastic Agents/pharmacology , Humans , Molecular Structure , Phenazines/chemical synthesis , Phenazines/chemistry , Phenazines/isolation & purification , Phenazines/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...